1. Introduction {#sec1}
===============

Cognitive impairment is common in Parkinson\'s disease (PD), even in its early stages. Mild cognitive impairment (MCI) may be identified in approximately 25% of newly diagnosed patients \[[@B1]\], and those PD patients are at a higher risk of developing dementia compared with normal cognition PD patients \[[@B2]--[@B4]\]. Parkinson\'s disease dementia (PDD) has a cumulative prevalence up to 75--90% of those with a disease duration of 10 years or more \[[@B5]\]. Cognitive impairment in PD patients includes attention deficits, executive dysfunction, visuospatial defects, free-recall memory problems, confrontation naming difficulties, as well as encoding deficits \[[@B6]--[@B8]\].

Diagnosis of PDD largely relies on neuropsychological measurements and evaluation. Four neuropsychological evaluation tools have been designed specifically for PD patients so far. Minimental Parkinson (MMP) and Parkinson Neuropsychometric Dementia Assessment (PANDA) are short screen tests for cognitive impairment in PD patients, but lack extensive clinimetric evaluation \[[@B9]--[@B11]\]. Scale for Outcomes of Parkinson\'s Disease-Cognition (SCOPA-COG) is a reliable and valid instrument for assessing "frontal-subcortical" function, but the "instrumental-cortical" function is missing \[[@B12]\], which has been identified in approximately 15--20% of PD patients \[[@B6]\]. Parkinson\'s disease-cognitive rating scale (PD-CRS), designed by Dr. Kulisevsky, is a comprehensive, reliable, and valid instrument for assessing both "frontal-subcortical" functions (sustained attention, working memory, alternating and action verbal fluencies, clock drawing, and immediate and delayed free-recall verbal memory) and "instrumental-cortical" functions (confrontation naming, copying a clock) \[[@B13]--[@B15]\]. China has over 2 million PD patients, but cognitive impairment is substantially underestimated because of the lack of a Chinese version neuropsychological evaluation tool specific for PD patients. The aims of the present study are to test the reliability and validity of the Chinese version PD-CRS; establish cutoff scores for diagnosis of PDD and PD-MCI; explore cognitive profiles of PD-MCI and PDD; and find cognitive deficits suggesting a transition from PD-MCI to PDD.

2. Materials and Methods {#sec2}
========================

2.1. Revised Chinese Version of PD-CRS {#sec2.1}
--------------------------------------

China has different culture and language systems from western countries. Therefore, three steps were executed to make ensure that the PD-CRS was adapted to Chinese people. First, the English version of PD-CRS was translated to a provisional Chinese version and was examined in a consensus meeting. Second, the provisional Chinese version of PD-CRS was administered to 15 Chinese healthy volunteers with age ranging from 60--85 and with 6 or more years of education. The preliminary test showed that senior Chinese people were not familiar with some of the pictures in the picture naming section, such as "jingle bell," "guitar," "berry," and "stool." The Spring Festival is the traditional festival in China, which is similar to the Christmas day in the West. It is a tradition to hang lanterns at the Spring Festival which is akin to hanging jingle bells on Christmas day. Thus, using "lantern" instead of "jingle bell" kept the difficulty level of naming. We made four modifications in the confrontation naming part: "lantern" replaced "jingle bell," "erhu" replaced "guitar," "strawberry" replaced "berry," and "chair" replaced "stool." All experts approved of these modifications in the picture-naming section in the consensus meeting. We also found that most of these senior Chinese people did not know English letters. We made the following changes to the "sustained attention," "working memory," and "alternating verbal fluency," with the help from Dr. Kulisevsky, the author of PD-CRS. The original instructions in the "sustained attention" section are to read an ascending series of letters and numbers to the subject, asking the subject to say how many letters are there in the series. In the revised Chinese version, the instructions are to read an ascending series of numbers to the subject, asking the subject to say how many odd numbers are there in the series. Thus, in both the original and revised instruction, the subjects need to memorize what they heard and be able to operate classification at the same time. The original instructions in the "working memory" section is to read aloud a randomized list of numbers and letters ranging in length from 2 to 6 letters and numbers. After each series, the subject is asked to repeat the numbers first, and then the letters. In the revised Chinese version, the instructions are to read aloud a randomized list of numbers in length from 2--6 numbers. After each series, the subject is asked to repeat the numbers backward. The revised method is similar to the backward digit span test and tests the subject\'s working memory. The original instructions in the "alternating verbal fluency" section asks the subject to generate as many different words as possible by alternating between words beginning with the letter "S" and articles of clothing for a 60-second duration. In the revised Chinese version, the instructions are to ask the subject to make as many different phrases as possible by alternating between providing words starting with the written form of Chinese character "发" pronounced as "fa" and articles of clothing for a 60-second duration. Third, after all modifications were completed, the newly revised Chinese version of PD-CRS was finally approved in a consensus meeting. The new version was then retested in 15 Chinese healthy volunteers. All the participants and examiners had good understanding and comprehensibility of the instructions. The revised Chinese version of PD-CRS was attached as supplementary material.

2.2. Subjects {#sec2.2}
-------------

A cohort of 92 PD patients were recruited from 3 centers, including the Neurology Department of Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine; Neurology Department of Nanjing Brain Hospital affiliated to Nanjing Medical University; and Neurology Department of the First Affiliated Hospital of China Medical University. The inclusion criteria for the enrollment were diagnosis of idiopathic PD according to the UK Brain Bank, ages of 60--85 years, and 6 or more years of education. The exclusion criteria were other neurological diseases, such as stroke, epilepsy, tumor, brain trauma (history and cranial MRI), and abnormalities on brain CT or MRI in the past 12 months; nutritional and metabolic abnormalities (folic acid or vitamin B12 or vitamin B1 deficiency); psychiatric problems for which who now or used to have psychiatric medicine dependence; serious sleep disorder; history of surgery under general anesthesia within the last year; evidence of physical illness; hearing or vision loss; and severe cardiac or respiratory disorders. This study protocol was approved by the Ethics Committee of Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine. Written informed consent was obtained from all participants in the study as well.

2.3. Assessments {#sec2.3}
----------------

For baseline, the collection of demographic and clinical data included age, gender, education, disease duration, past disease history (diabetes, hypertension, coronary heart disease, and cerebrovascular disease), current medications converted to levodopa equivalent daily dose (LEDD), history of smoking or alcohol consumption, the Unified Parkinson\'s Disease Rating Scale part III (UPDRS-III), Beck Depression Inventory (BDI), and PD-CRS. For the second visit, the same neurologist evaluated the same patient with PD-CRS after 2 weeks. For the third visit, another neurologist evaluated the same patient with PD-CRS, Mattis Dementia Rating Scale (MDRS) and Clinical Dementia Rating (CDR) in an interval of 6 ± 2 weeks from the second visit. Based on CDR, the PD patients were divided into PD-NC, PD-MCI, and PDD subgroups; CDR = 0 in the PD-NC group, CDR = 0.5 in the PD-MCI group, and CDR ≥1 in the PDD group.

2.4. Statistical Analysis {#sec2.4}
-------------------------

All continuous demographic and clinical data were presented as mean ± SD and compared by Analysis Of Variance (ANOVA) or Kruskal--Wallis test. All categorical variables were presented as numbers and estimated by Chi-squared test. Normality of distribution was evaluated by Kolmogorov--Smirnov (K--S) test initially. Test-retest reliability and inter-rater reliability were assessed by intraclass correlation coefficients (ICCs). The ICC is equal to the degree of individual variation divided by the total variability, so the value is between 0 and 1. Landis and Koch recommend ICC should be more than 0.80; 0.61--0.80 classified as good; 0.41--0.60 as fair, 0.11--0.40 as low, and 0.1 or less as no consistency. Internal consistency reliability was evaluated by the Cronbach\'s alpha coefficient (≥0.80 was considered acceptable) and the corrected item-total correlation (≥0.40 was considered acceptable). Acceptability rating was determined as acceptable for each PD-CRS item if there was \<5% of missing data rates and \<15% of the floor/ceiling effects (floor: the proportion of patients with the minimum possible score; ceiling: the proportion of patients with the maximum possible score). Receiver operator characteristic (ROC) curves were generated to identify the discriminative power of PD-CRS for diagnosing PD-MCI and PDD. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratios (LR+), and negative likelihood ratios (LR−) were calculated. The appropriate cutoff point was chosen according to the maximum combined sensitivity and specificity. All tests were two-sided, and the results were considered statistically significant at *p* \< 0.05. Statistical analysis was performed using SPSS 20.0.

3. Results {#sec3}
==========

3.1. Demographic and Clinical Data {#sec3.1}
----------------------------------

The demographic and clinical data were presented in [Table 1](#tab1){ref-type="table"}. Of the 92 PD patients, 37 were classified into the PD-NC group, 44 into the PD-MCI group, and 11 into the PDD group. The distributions of age, gender, education, history of smoking, alcohol consumption, diabetes, hypertension, coronary heart disease, and cerebrovascular disease were similar between the groups (*p* \> 0.05). There were significant differences in disease duration, H--Y staging, LEDD, UPDRS-III, BDI, and MDRS scores among the three groups (*p* \< 0.05). PDD patients have longer disease duration, higher scores of UPDRS-III and BDI, and lower scores of MDRS.

3.2. Reliability {#sec3.2}
----------------

Cronbach\'s alpha was used to measure internal consistency of the PD-CRS scale. The PD-CRS showed a high internal consistency among all items in this scale (Cronbach\'s Alpha = 0.840). Correction item − total correlation ranged from 0.452 (confrontation naming) to 0.730 (alternating verbal fluencies) ([Table 2](#tab2){ref-type="table"}). No item improved Cronbach\'s alpha (0.840) if removed. As for the test-retest reliability, the intraclass correlation coefficient (ICC) for each item score of the PD-CRS is presented in [Table 2](#tab2){ref-type="table"}. ICC of the total score of PD-CRS reached 0.906 (95% CI 0.860--0.935, *p* \< 0.001), which indicated high test-retest reliability. ICC of each item ranged from 0.691 to 0.825 (*p* \< 0.001). For inter-rater reliability ([Table 2](#tab2){ref-type="table"}), the ICC of the total PD-CRS score was 0.899 (95% CI 0.848--0.933, *p* \< 0.001), and the ICC of each item ranged from 0.592 to 0.826 (*p* \< 0.001). These results indicated that the revised Chinese version of PD-CRS has good internal consistency, test-retest reliability, and inter-rater reliability according to the criteria mentioned in [Section 2.4](#sec2.4){ref-type="sec"}.

3.3. Acceptability {#sec3.3}
------------------

Ceiling effect (\>15% of the respondents with the highest possible score) and floor effect (\>15% of the respondents with the lowest possible score) were analyzed. Nonfloor effects were observed for the total, subcortical, and cortical scores of the PD-CRS when analyzed in all PD patients, specifically PD-NC and PD-MCI subgroup ([Table 3](#tab3){ref-type="table"}, Supplementary Tables [](#supplementary-material-1){ref-type="supplementary-material"} and [](#supplementary-material-1){ref-type="supplementary-material"}). But in the PDD subgroup, items of immediate free-recall verbal memory, confrontation naming, sustained attention, working memory, alternating verbal fluencies, and delayed free-recall verbal memory showed floor effects (Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}), indicating that those cognitive functions were severely and commonly impaired in PDD patients. The ceiling effect was observed in confrontation naming (15.2%), clock drawing (32.6%), and copying a clock (72.8%) ([Table 3](#tab3){ref-type="table"}) when analyzed in whole PD patients, and more items (confrontation naming 21.6%, sustained attention 21.6%, clock drawing 54.1% and copying a clock 86.5%) showed ceiling effects in the PD-NC subgroup (Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}), whereas only copying a clock showed the ceiling effect (20.5%) in the PD-MCI subgroup (Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}), indicating that the ceiling effects were mainly due to the PD-NC group.

3.4. Concurrent and Discriminative Validity {#sec3.4}
-------------------------------------------

Concurrent validity was analyzed in total PD-CRS scores with MDRS scores, as well as subscales of PD-CRS with corresponding parts of MDRS ([Table 4](#tab4){ref-type="table"}). PD-CRS showed fair concurrent validity with the MDRS scores (ICC = 0.731, 95% CI 0.602--0.816). The concurrent validity of PD-CRS-working memory with the digit span forward and backward subtest (A) of MDRS (ICC = 0.408, 95% CI 0.223--0.577); alternating verbal fluencies with initiation-preservation subscale (E) of MDRS (ICC = 0.470, 95% CI 0.261--0.625); and delayed free-recall verbal memory with free memory (AF + AG) of MDRS (ICC = 0.638, 95% CI 0.503--0.749) are shown in [Table 4](#tab4){ref-type="table"}. These results show that the concurrent validity of subscales of PD-CRS with corresponding parts of MDRS only reach the fair scope of ICC (0.41--0.60) according to the criteria recommended by Landis and Koch. We think it is due to the different difficulty degrees of these two scales. For example, the working memory subscale of PD-CRS is a randomized list of numbers in length from 2--6 numbers and asking the subject to repeat the numbers backward. In digit span test of MDRS, it is a randomized list of numbers in length 2--4.

For discriminative validity, significant differences were observed in total PD-CRS, frontal-subcortical functions, and instrumental-cortical functions, and each PD-CRS item scores among PD-NC, PD-MCI, and PDD groups (*p* \< 0.001) ([Table 5](#tab5){ref-type="table"}). PD-MCI and PDD patients perform differently when compared with PD-NC patients. The frontal-subcortical items showed a significant decrease in the PD-MCI subgroup compared with the PD-NC subgroup (*p* \< 0.05), but the instrument cortical items did not (confrontation naming *p*=0.717 and copying a clock *p*=0.620), which means that the cortical functions are relatively intact in PD-MCI patients (instrumental-cortical functions, *p*=0.203), but the subcortical functions are impaired (frontal-subcortical functions, *p* \< 0.001). All the frontal-subcortical and instrumental-cortical functions showed significant decline in the PDD subgroup compared with the PD-NC subgroup, which indicates that PDD patients had global cognitive impairment. PDD patients had lowered scores in cortical functions than PD-MCI patients (instrumental-cortical functions 21.64 ± 4.523 vs. 26.66 ± 2.272, *p*=0.004; confrontation naming 14.91 ± 2.809 vs. 17.09 ± 2.351, *p*=0.051; copying a clock 6.73 ± 3.495 vs. 9.57 ± 0.818, *p* \< 0.001), but there was no significant difference between PD-MCI and PDD in some of the subcortical functions, such as working memory (*p*=0.168), clock drawing (*p*=0.143), and alternating verbal fluencies (*p*=0.069).

Comparative progression of impairment of "frontal-subcortical functions" and "instrumental-cortical functions" showed that those cortical functions (confrontation naming, copying a clock) are relatively normal in PD-MCI, but had abrupt decline in the PDD group (Figures [1(a)](#fig1){ref-type="fig"}[1(b)](#fig1){ref-type="fig"}). Subcortical functions had marked decline in both PD-MCI and PDD. Sustained attention and action verbal fluencies were listed as examples (Figures [1(c)](#fig1){ref-type="fig"} and [1(d)](#fig1){ref-type="fig"}). These results indicated that PD-MCI patients and PDD patients have different cognitive impairment profiles and patterns. The worse performance in cortical functions of PDD patients than PD-MCI patients showed a pattern of cognitive impairment transition from PD-MCI to PDD.

3.5. Discriminative Power of PD-CRS for Diagnosing PD-MCI and PDD {#sec3.5}
-----------------------------------------------------------------

ROC curve indicated that a PD-CRS total score of 80.5 raised the maximum cutoff accuracy for detecting PD-MCI (AUC: 0.803, 95% CI: 0.709--0.898, *p* \< 0.001, sensitivity 75.7%, specificity 75.0%, PPV 75.2%, and NPV 75.5%) ([Figure 2](#fig2){ref-type="fig"}, [Table 6](#tab6){ref-type="table"}). The PD-CRS total score of 73.5 is the maximum accuracy cutoff for detecting PDD (AUC: 0.984, 95% CI: 0.957--1.000, *p* \< 0.001, sensitivity 89.2%, specificity 98.9%, PPV 98.8%, and NPV 90.1%) ([Figure 2](#fig2){ref-type="fig"}, [Table 6](#tab6){ref-type="table"}).

4. Discussion {#sec4}
=============

This Chinese version of PD-CRS was revised based on the culture background of Chinese people. Our results showed that the revised Chinese version of PD-CRS is a reliable, acceptable, valid, and useful neuropsychological battery that could accurately diagnose PDD as proven in previous reports \[[@B13], [@B14]\]. The PD-CRS showed a high internal consistency, test-retest reliability, and inter-rater reliability. The Chinese version of PD-CRS showed fair concurrent validity with the Chinese version of MDRS. No floor effects were observed in the total score of PD-CRS and individual items in whole PD patients, PD-NC, and PD-MCI subgroups; but items of immediate free-recall verbal memory, confrontation naming, sustained attention, working memory, alternating verbal fluencies, and delayed free-recall verbal memory showed floor effects in the PDD group, indicating that PDD patients were commonly and severely impaired in these functions. Ceiling scores were found in confrontation naming, clock drawing, and copying a clock in PD patients analyzed as a whole, but the ceiling scores were mainly distributed among PD-NC patients, and those items were still able to discriminate cognitive impairments in PD-MCI and PDD patients.

There is a spectrum of cognitive dysfunction, ranging from MCI to dementia in PD patients \[[@B16]\]. Executive dysfunction, impaired verbal fluency, visuospatial deficits, as well as encoding memory dysfunction are cognitive profiles of PD-MCI \[[@B6]--[@B8]\]. At later stages, both subcortical and cortical functions might be impaired \[[@B17]\]. PD-MCI subjects differed from PD-NC patients in all frontal-subcortical items, whereas the two instrumental-cortical functions items were relatively intact in PD-MCI patients, but were selectively impaired in PDD patients. These results showed different cognitive impairment patterns between PD-MCI and PDD patients. The cutoff value for diagnosis of PD-MCI is 80.5 with the sensitivity of 75.7% and the specificity of 75.0%. PD-MCI subjects are at a higher risk to develop dementia compared with normal cognition PD patients; thus, the discriminant ability to diagnose PD-MCI by the PD-CRS suggests that this scale may be a good instrument for screening purposes. PD-CRS could accurately diagnose PDD, and the cutoff value for diagnosis of PDD is 73.5 with the sensitivity of 89.2% and the specificity of 98.9%. PDD patients showed a significant difference with PD-NC in all subcortical and cortical items, indicating PDD patients had global cognitive impairments.

There were two limitations in the present study. First, we have small sample of PDD patients which might cause bias to some results, such as the high level of floor effects in PDD subgroups. Second, PD patients with high BDI scores which might act as a confounding factor for cognitive function test were not excluded. There were 7 out of 44 PD-MCI patients (15.91%) and 4 out of 11 PDD patients (36.36%) who had BDI scores ≥20. The cognitive function was analyzed between BDI \<20 and BDI ≥20 in PD-MCI and PDD subgroups separately. The results showed that PD-CRS total score and each item score have no significant difference between BDI \<20 and BDI ≥20 scores in both PD-MCI and PDD subgroups (Supplementary Tables [](#supplementary-material-1){ref-type="supplementary-material"} and [](#supplementary-material-1){ref-type="supplementary-material"}). A link between mood symptoms and cognitive impairment in PD has been found, but studies have been inconsistent regarding the relationship between mood symptoms and cognitive function. Ng et al. did not find significant correlation between early depression and cognitive function in both baseline and follow-up tests \[[@B18]\]. Jones et al. reported that depressive symptoms may be a harbinger for future cognitive decline among PD patients \[[@B19]\]. Petkus et al. found that poorer cognitive performance, across all cognitive domains, was a risk factor for increased symptoms of anxiety and depression \[[@B20]\]. In the present study, although we did not find significant difference of cognitive function between different BDI scores subgroups, it would be better to match BDI scores between subgroups to exclude the potential effects of depression on cognitive test.

5. Conclusion {#sec5}
=============

Overall, our results showed that the Chinese version of PD-CRS is an applicable and valid tool for assessing cognition in PD patients. It is sensitive in detecting the cognitive impairment transition from predominantly subcortical impairments in PD-MCI patients to global cognitive decline in PDD patients.
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Click here for additional data file.

![Comparative progression of impairment of "frontal-subcortical functions" and "instrumental-cortical functions" in PD-NC, PD-MCI, and PDD subgroups (mean ± SE). Cortical functions (confrontation naming and copying a clock) are relatively normal in PD-MCI, but had abrupt decline in the PDD group (a and b). Sustained attention and action verbal fluencies were used as examples to show marked decline of subcortical functions in both PD-MCI and PDD (c and d).](PD2020-5289136.001){#fig1}

![Discriminative power of PD-CRS for diagnosing PD-MCI and PDD. AUC for differentiating PD-MCI is 0.803, 95% CI: 0.709--0.898, *p* \< 0.001. AUC for detecting PDD is 0.984, 95% CI: 0.957--1.000, *p* \< 0.001.](PD2020-5289136.002){#fig2}

###### 

Demographic and clinical characteristics between PD-NC, PD-MCI, and PDD groups.

                                PD-NC              PD-MCI             PDD                *p*
  ----------------------------- ------------------ ------------------ ------------------ ------------
  *N*                           37                 44                 11                 ---
  Age                           68.08 ± 6.202      69.82 ± 6.366      71.27 ± 4.563      0.237^a^
  Male (%)                      25 (67.6%)         34 (77.3%)         7 (63.6%)          0.511^b^
  Education (year)              12.35 ± 2.879      11.63 ± 3.441      10.73 ± 2.284      0.225^c^
  Disease duration (year)       5.32 ± 5.716       5.18 ± 3.598       7.82 ± 3.401       0.033^c^
  H--Y staging                  1.70 ± 0.6714      1.90 ± 0.6522      2.45 ± 0.650       0.009^c^
  Smoke (−)                     34 (91.9%)         38 (86.4%)         10 (90.9%)         0.712^b^
  Alcohol (−)                   34 (91.9%)         39 (88.6%)         9 (81.8%)          0.656^b^
  Diabetes (−)                  32 (86.5%)         39 (88.6%)         9 (81.8%)          0.838^b^
  Hypertension (−)              27 (73.0%)         29 (65.9%)         7 (63.6%)          0.739^b^
  Coronary heart disease (−)    31 (83.8%)         36 (81.8%)         11 (100%)          0.139^b^
  Cerebrovascular disease (−)   33 (89.2%)         39 (88.6%)         10 (90.0%)         0.976^b^
  Levodopa (+)                  25 (67.6%)         36% (81.8%)        10 (90.0%)         0.151^b^
  Dopamine agonists (+)         22 (59.5%)         20 (45.5%)         5 (45.5%)          0.418^b^
  COMT inhibitor (+)            3 (8.1%)           10 (22.7%)         0 (0%)             0.061^b^
  MAO-B inhibitor (+)           13 (35.1%)         8 (18.2%)          1 (9.1%)           0.090^b^
  Anticholinergic (+)           0 (0%)             2 (4.5%)           1 (9.1%)           0.177^b^
  Amantadine (+)                3 (8.1%)           7 (15.9%)          2 (18.2%)          0.488^b^
  LEDD (mg/d)                   323.97 ± 249.571   430.73 ± 287.325   540.91 ± 301.719   0.038^a^
  UPDRS-III                     12.89 ± 8.906      20.48 ± 13.473     26.00 ± 11.773     0.001^c^
  BDI                           5.68 ± 4.295       11.45 ± 8.019      16.45 ± 10.727     \<0.001^c^
  MDRS                          138.16 ± 6.265     131.43 ± 9.260     114.27 ± 15.755    \<0.001^c^

^a^One-way analysis of variance (ANOVA); ^b^Chi-square test; ^c^Kruskal--Wallis test. PD: Parkinson\'s disease; PD-NC: PD patients with normal cognition; PD-MCI: PD patients with mild cognitive impairment; PDD: PD patients with dementia; H--Y staging: Hoehn and Yahr staging; COMT inhibitor: catechol O-methyltransferase inhibitor; MAO-B inhibitor: monoamine oxidase-B inhibitor; LEDD: levodopa equivalent daily dose; UPDRS-III: the Unified Parkinson\'s Disease Rating Scale part III; BDI: Beck Depression Inventory; MDRS: Mattis Dementia Rating Scale.

###### 

Reliability and internal consistency for both total and individual item scores of PD-CRS.

  Subscale                              Test-retest reliability   Inter-rater reliability   Internal consistency                                         
  ------------------------------------- ------------------------- ------------------------- ---------------------- --------- --------------------------- -------
  Immediate free-recall verbal memory   0.817 (0.747--0.867)      \<0.001                   0.692 (0.580--0.782)   \<0.001   0.705                       0.830
  Confrontation naming                  0.717 (0.554--0.844)      \<0.001                   0.709 (0.562--0.807)   \<0.001   0.452                       0.837
  Sustained attention                   0.810 (0.743--0.867)      \<0.001                   0.775 (0.667--0.857)   \<0.001   0.704                       0.829
  Working memory                        0.706 (0.571--0.808)      \<0.001                   0.650 (0.521--0.759)   \<0.001   0.602                       0.835
  Clock drawing                         0.728 (0.506--0.851)      \<0.001                   0.675 (0.449--0.822)   \<0.001   0.629                       0.834
  Copying a clock                       0.814 (0.423--0.925)      \<0.001                   0.826 (0.429--0.922)   \<0.001   0.566                       0.838
  Delayed free-recall verbal memory     0.825 (0.743--0.894)      \<0.001                   0.748 (0.614--0.845)   \<0.001   0.665                       0.829
  Alternating verbal fluencies          0.727 (0.608--0.815)      \<0.001                   0.592 (0.471--0.693)   \<0.001   0.730                       0.822
  Action verbal fluencies               0.691 (0.562--0.796)      \<0.001                   0.720 (0.596--0.821)   \<0.001   0.711                       0.821
  Frontal-subcortical functions         0.911 (0.865--0.939)      \<0.001                   0.893 (0.841--0.929)   \<0.001   0.977                       0.787
  Instrumental-cortical functions       0.780 (0.632--0.870)      \<0.001                   0.789 (0.655--0.872)   \<0.001   0.645                       0.829
  PD-CRS                                0.906 (0.860--0.935)      \<0.001                   0.899 (0.848--0.933)   \<0.001   Cronbach\'s alpha = 0.840   

PD-CRS: Parkinson\'s disease-cognitive rating scale; ICC: intraclass correlation coefficients; CI: confidence interval.

###### 

Acceptability of PD-CRS.

  Item                                  Mean ± SD        Min-max   Skewness   Kurtosis   Floor effect (%)   Ceiling effect (%)
  ------------------------------------- ---------------- --------- ---------- ---------- ------------------ --------------------
  Immediate free-recall verbal memory   7.32 ± 2.693     0--12     −0.154     −0.653     1.1                6.5
  Confrontation naming                  17.02 ± 2.580    10--20    −1.131     0.840      4.3                15.2
  Sustained attention                   5.90 ± 2.894     0--10     −0.357     −0.822     4.3                10.8
  Working memory                        5.34 ± 2.190     0--10     0.481      −0.177     1.1                5.4
  Clock drawing                         8.00 ± 2.335     0--10     −1.467     1.812      1.1                32.6
  Copying a clock                       9.34 ± 1.639     0--10     −4.018     18.591     1.1                72.8
  Delayed free-recall verbal memory     5.72 ± 3.068     0--12     −0.124     −0.829     6.5                1.1
  Alternating verbal fluencies          7.50 ± 4.040     0--16     −0.191     −0.438     6.5                2.2
  Action verbal fluencies               9.18 ± 4.501     0--24     0.417      0.300      2.2                1.1
  Frontal-subcortical functions         48.96 ± 15.777   11--82    −0.382     −0.357     2.2                1.1
  Instrumental-cortical functions       26.36 ± 3.274    15--30    −1.441     2.082      1.1                13.0
  PD-CRS total score                    75.32 ± 17.818   30--109   −0.533     −0.092     1.1                1.1

PD-CRS: Parkinson\'s disease-cognitive rating scale; SD: standard deviation.

###### 

Validity of PD-CRS.

                                                         MDRS                       
  ------------------------------------------------------ ------- ------------------ ---------
  PD-CRS total score                                     0.731   \[0.602, 0.816\]   \<0.001
  Working memory vs. MDRS (A)                            0.408   \[0.223, 0.577\]   \<0.001
  Alternating verbal fluencies vs. MDRS (E)              0.470   \[0.261, 0.625\]   \<0.001
  Delayed free-recall verbal memory vs. MDRS (AF + AG)   0.638   \[0.503, 0.749\]   \<0.001

PD-CRS: Parkinson\'s disease-cognitive rating scale; MDRS: Mattis Dementia Rating Scale; ICC: intraclass correlation coefficients; CI: confidence interval.

###### 

Comparisons of PD-CRS between PD-NC, PD-MCI, and PDD groups.

                                        PD-NC            PD-MCI           PDD              *p*          PD-NC vs. PD-MCI^c^   PD-NC vs. PDD^c^   PD-MCI vs. PDD^c^
  ------------------------------------- ---------------- ---------------- ---------------- ------------ --------------------- ------------------ -------------------
  Immediate free-recall verbal memory   8.81 ± 2.132     6.70 ± 2.681     4.73 ± 1.191     \<0.001^a^   \<0.001               \<0.001            0.014
  Confrontation naming                  17.57 ± 2.523    17.09 ± 2.351    14.91 ± 2.809    0.008^b^     0.717                 0.006              0.051
  Sustained attention                   7.46 ± 2.116     5.32 ± 2.785     3.00 ± 2.646     \<0.001^a^   \<0.001               \<0.001            0.008
  Working memory                        6.46 ± 2.445     4.82 ± 1.618     3.64 ± 1.362     \<0.001^b^   0.012                 0.001              0.168
  Clock drawing                         9.05 ± 1.311     7.82 ± 2.026     5.18 ± 3.573     \<0.001^b^   0.007                 \<0.001            0.143
  Copying a clock                       9.84 ± 0.442     9.57 ± 0.818     6.73 ± 3.495     \<0.001^b^   0.620                 \<0.001            \<0.001
  Delayed free-recall verbal memory     7.43 ± 2.714     5.11 ± 2.572     2.36 ± 2.420     \<0.001^a^   \<0.001               \<0.001            0.002
  Alternating verbal fluencies          9.70 ± 3.566     6.64 ± 3.577     3.55 ± 3.045     \<0.001^b^   0.004                 \<0.001            0.069
  Action verbal fluencies               10.97 ± 4.213    8.77 ± 4.220     4.82 ± 3.219     \<0.001^a^   0.019                 \<0.001            0.005
  Frontal-subcortical functions         59.89 ± 10.448   45.18 ± 12.901   27.27 ± 11.577   \<0.001^a^   \<0.001               \<0.001            \<0.001
  Instrumental-cortical functions       27.41 ± 2.682    26.66 ± 2.272    21.64 ± 4.523    \<0.001^b^   0.203                 \<0.001            0.004
  PD-CRS total score                    87.30 ± 11.244   71.84 ± 14.144   48.91 ± 14.916   \<0.001^a^   \<0.001               \<0.001            \<0.001

PD-CRS: Parkinson\'s disease-cognitive rating scale; PD: Parkinson\'s disease; PD-NC: PD patients with normal cognition; PD-MCI: PD patients with mild cognitive impairment; PDD: PD patients with dementia. ^a^One-way analysis of variance (ANOVA); ^b^Kruskal--Wallis test; ^c^Bonferroni test.

###### 

Accuracy measures of PD-CRS.

  Scale version              Cutoff     Sensitivity (%)   Specificity (%)   PPV (%)    NPV (%)     LR (+)     LR (−)
  -------------------------- ---------- ----------------- ----------------- ---------- ----------- ---------- --------
  PD-NC/PD-MCI (AUC 0.803)   78.5       78.4              65.9              69.7       75.3        2.29       0.33
  **80.5**                   **75.7**   **75.0**          **75.2**          **75.5**   **3.03**    **0.32**   
  81.5                       73.0       77.3              76.3              74.1       3.22        0.35       
                                                                                                              
  PD-MCI/PDD (AUC 0.864)     54.5       90.9              63.6              71.4       87.5        2.49       0.14
  **57.5**                   **84.1**   **72.7**          **75.5**          **82.1**   **3.08**    **0.22**   
  58.5                       77.3       72.7              73.9              76.2       2.83        0.31       
                                                                                                              
  PD-NC/PDD (AUC 0.984)      69.0       94.6              90.9              91.2       94.4        10.39      0.06
  **73.5**                   **89.2**   **98.9**          **98.8**          **90.1**   **81.09**   **0.11**   
  75.0                       86.5       99.6              99.5              88.1       216.25      0.14       

PD-CRS: Parkinson\'s disease-cognitive rating scale; SD: standard deviation; PD: Parkinson\'s disease; PD-NC: PD patients with normal cognition; PD-MCI: PD patients with mild cognitive impairment; PDD: PD patients with dementia; AUC: area under the curve; PPV: positive predictive value; NPV: negative predictive value; LR+: positive likelihood ratio; LR−: negative likelihood ratio.

[^1]: Guest Editor: Ji Hyun Ko
